Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic
renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability,
and efficacy.